212 related articles for article (PubMed ID: 29880602)
21. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
22. LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.
Layer JH; Alford CE; McDonald WH; Davé UP
Mol Cell Biol; 2016 Feb; 36(3):488-506. PubMed ID: 26598604
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract][Full Text] [Related]
24. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
25. Identification of genes potentially involved in LMO2-induced leukemogenesis.
Davenport J; Neale GA; Goorha R
Leukemia; 2000 Nov; 14(11):1986-96. PubMed ID: 11069036
[TBL] [Abstract][Full Text] [Related]
26. The LMO2 oncogene regulates DNA replication in hematopoietic cells.
Sincennes MC; Humbert M; Grondin B; Lisi V; Veiga DF; Haman A; Cazaux C; Mashtalir N; Affar el B; Verreault A; Hoang T
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1393-8. PubMed ID: 26764384
[TBL] [Abstract][Full Text] [Related]
27. T-ALL can evolve to oncogene independence.
Abdulla H; Vo A; Shields BJ; Davies TJ; Jackson JT; Alserihi R; Viney EM; Wong T; Yan F; Wong NC; Demoen L; Curtis DJ; Alexander WS; Van Vlierberghe P; Dickins RA; McCormack MP
Leukemia; 2021 Aug; 35(8):2205-2219. PubMed ID: 33483615
[TBL] [Abstract][Full Text] [Related]
28. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
[TBL] [Abstract][Full Text] [Related]
30. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.
Yamada Y; Warren AJ; Dobson C; Forster A; Pannell R; Rabbitts TH
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3890-5. PubMed ID: 9520463
[TBL] [Abstract][Full Text] [Related]
31. Etv2 is expressed in the yolk sac hematopoietic and endothelial progenitors and regulates Lmo2 gene expression.
Koyano-Nakagawa N; Kweon J; Iacovino M; Shi X; Rasmussen TL; Borges L; Zirbes KM; Li T; Perlingeiro RC; Kyba M; Garry DJ
Stem Cells; 2012 Aug; 30(8):1611-23. PubMed ID: 22628281
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
33. LMO2 is essential to maintain the ability of progenitors to differentiate into T-cell lineage in mice.
Hirano KI; Hosokawa H; Koizumi M; Endo Y; Yahata T; Ando K; Hozumi K
Elife; 2021 Aug; 10():. PubMed ID: 34382935
[TBL] [Abstract][Full Text] [Related]
34. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
[TBL] [Abstract][Full Text] [Related]
35. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
Kim SH; Kim EJ; Hitomi M; Oh SY; Jin X; Jeon HM; Beck S; Jin X; Kim JK; Park CG; Chang SY; Yin J; Kim T; Jeon YJ; Song J; Lim YC; Lathia JD; Nakano I; Kim H
Cell Death Differ; 2015 Sep; 22(9):1517-25. PubMed ID: 25721045
[TBL] [Abstract][Full Text] [Related]
36. Activation of the
Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
[TBL] [Abstract][Full Text] [Related]
37. HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.
Calero-Nieto FJ; Joshi A; Bonadies N; Kinston S; Chan WI; Gudgin E; Pridans C; Landry JR; Kikuchi J; Huntly BJ; Gottgens B
Oncogene; 2013 Nov; 32(48):5471-80. PubMed ID: 23708655
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
39. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations.
Brar N; Butzmann A; Kumar J; Peerani R; Morgan EA; Grigoriadis G; Kumar B; Tatarczuch RM; Warnke RA; Ohgami RS
Histopathology; 2020 Dec; 77(6):984-988. PubMed ID: 32526041
[TBL] [Abstract][Full Text] [Related]
40. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
